High	O
-	O
Dose	O
celecoxib	O
and	O
metronomic	O
"	O
low	O
-	O
dose	O
"	O
cyclophosphamide	O
is	O
an	O
effective	O
and	O
safe	O
therapy	O
in	O
patients	O
with	O
relapsed	O
and	O
refractory	O
aggressive	O
histology	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
.	O

PURPOSE	O
:	O
Angiogenesis	O
is	O
increased	O
in	O
aggressive	O
histology	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
and	O
may	O
be	O
a	O
target	O
with	O
selective	O
cyclooxygenase	O
-	O
2	O
inhibition	O
and	O
metronomic	O
chemotherapy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
assessed	O
response	O
,	O
toxicity	O
,	O
and	O
biomarkers	O
of	O
angiogenesis	O
to	O
low	O
-	O
dose	O
cyclophosphamide	O
(	O
50	O
mg	O
p	O
.	O
o	O
.	O
o	O
.	O
d	O
.	O
)	O
and	O
high	O
-	O
dose	O
celecoxib	O
(	O
400	O
mg	O
p	O
.	O
o	O
.	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
in	O
adult	O
patients	O
with	O
relapsed	O
or	O
refractory	O
aggressive	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
in	O
a	O
multicenter	O
phase	O
II	O
prospective	O
study	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
of	O
35	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
are	O
evaluable	O
for	O
response	O
.	O

Patients	O
had	O
primarily	O
relapsed	O
diffuse	O
large	O
B	B-Cancer
-	I-Cancer
cell	I-Cancer
lymphoma	I-Cancer
(	O
63	O
%	O
)	O
were	O
heavily	O
pretreated	O
(	O
median	O
of	O
three	O
regimens	O
)	O
and	O
high	O
risk	O
(	O
79	O
%	O
international	O
prognostic	O
index	O
,	O
greater	O
than	O
or	O
=	O
2	O
)	O
and	O
34	O
%	O
were	O
relapsed	O
after	O
autologous	O
stem	B-Cell
cell	I-Cell
transplant	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
8	O
.	O
4	O
months	O
,	O
the	O
overall	O
best	O
response	O
rate	O
is	O
37	O
%	O
(	O
2	O
complete	O
clinical	O
response	O
/	O
complete	O
clinical	O
response	O
unconfirmed	O
and	O
9	O
partial	O
response	O
)	O
,	O
with	O
22	O
%	O
achieving	O
stable	O
disease	O
.	O

Median	O
overall	O
and	O
progression	O
-	O
free	O
survivals	O
are	O
14	O
.	O
4	O
and	O
4	O
.	O
7	O
months	O
,	O
respectively	O
.	O

The	O
median	O
response	O
duration	O
was	O
8	O
.	O
2	O
months	O
.	O

The	O
most	O
common	O
toxicity	O
was	O
skin	B-Organ
rash	O
(	O
40	O
%	O
)	O
;	O
myelosuppression	O
and	O
gastrointestinal	B-Organism_subdivision
side	O
effects	O
were	O
uncommon	O
.	O

Three	O
patients	O
developed	O
deep	B-Pathological_formation
vein	I-Pathological_formation
thromboses	I-Pathological_formation
and	O
two	O
heavily	O
pretreated	O
patients	O
developed	O
treatment	O
-	O
related	O
acute	B-Cancer
myelogenous	I-Cancer
leukemia	I-Cancer
or	O
myelodysplasia	B-Pathological_formation
after	O
3	O
.	O
7	O
and	O
12	O
months	O
of	O
therapy	O
.	O

Circulating	O
endothelial	B-Cell
cells	I-Cell
and	O
their	O
precursors	B-Cell
declined	O
and	O
remained	O
low	O
in	O
responders	O
,	O
whereas	O
plasma	B-Organism_substance
vascular	O
endothelial	O
growth	O
factor	O
trended	O
to	O
decline	O
in	O
responding	O
patients	O
but	O
increase	O
in	O
nonresponders	O
.	O

Trough	O
celecoxib	O
levels	O
achieved	O
targeted	O
"	O
antiangiogenic	O
"	O
levels	O
.	O

CONCLUSIONS	O
:	O
Low	O
-	O
dose	O
cyclophosphamide	O
and	O
high	O
-	O
dose	O
celecoxib	O
is	O
well	O
tolerated	O
and	O
active	O
in	O
pretreated	O
aggressive	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
.	O

Close	O
surveillance	O
for	O
arterial	B-Multi-tissue_structure
and	O
venous	B-Multi-tissue_structure
thrombotic	O
events	O
is	O
recommended	O
.	O

The	O
decline	O
in	O
circulating	B-Cell
endothelial	I-Cell
cells	I-Cell
and	O
their	O
precursors	B-Cell
suggests	O
that	O
this	O
combination	O
may	O
be	O
working	O
by	O
inhibiting	O
angiogenesis	O
but	O
should	O
be	O
validated	O
in	O
a	O
larger	O
patient	O
sample	O
.	O

